Prognostic and predictive value of a novel immuno-proliferative biomarker signature for targeted therapy efficacy in non-small cell lung cancer
High IFN-γ expression, low Ki-67 and MA levels, and ≤ 2 elevated LCTM components constitute a favorable biomarker profile for predicting response to targeted therapy in advanced NSCLC. These biomarkers could aid in predicting early response and therapeutic stratification. The proposed "driver-clone-dependent clone" co-regulation mechanism underscores the clinical value of multi-biomarker evaluation. Further multi-center prospective studies are warranted for validation.
Authors
- Xin Han (ORCID: https://orcid.org/0000-0002-9620-7502)
- Rong Lin
- Hongzhen Wang
- Xiaolei Zhang
- Wei Wei
- Ruixiang Gao
Institutions
- Wenzhou Medical University (CN)
- Dongyang People's Hospital (CN)
Publication Details
- Journal
- European journal of medical research
- Published
- 2026-03-09
- DOI
- https://doi.org/10.1186/s40001-026-03991-z
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00